Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Raw Materials (2023 - 2025)

Historic Raw Materials for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $1.0 million.

  • Phathom Pharmaceuticals' Raw Materials fell 5002.48% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 5002.48%. This contributed to the annual value of $1.7 million for FY2024, which is 20819.96% up from last year.
  • Phathom Pharmaceuticals' Raw Materials amounted to $1.0 million in Q3 2025, which was down 5002.48% from $991000.0 recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Raw Materials peaked at $2.0 million during Q3 2024, and registered a low of $111000.0 during Q2 2023.
  • Moreover, its 3-year median value for Raw Materials was $999500.0 (2025), whereas its average is $990600.0.
  • In the last 5 years, Phathom Pharmaceuticals' Raw Materials surged by 171711.71% in 2024 and then plummeted by 5002.48% in 2025.
  • Over the past 3 years, Phathom Pharmaceuticals' Raw Materials (Quarter) stood at $561000.0 in 2023, then skyrocketed by 208.2% to $1.7 million in 2024, then tumbled by 41.7% to $1.0 million in 2025.
  • Its Raw Materials was $1.0 million in Q3 2025, compared to $991000.0 in Q2 2025 and $1.4 million in Q1 2025.